The need for longer time horizons for cost-utility evaluation in bullous pemphigoid

Abstract

We read with interest the article from Mason et al offering a cost-effectiveness analysis comparing doxycycline and prednisolone as initial treatment for bullous pemphigoid (BP). ¹ As a prospective cost-utility analysis auxiliary to a multi-centre randomised controlled trial² with robust statistical modelling, the study is methodologically sound. The time horizon of the study was twelve months and the primary outcomes sought were short-term effectiveness and long-term safety.

This article is protected by copyright. All rights reserved.